MA45130B1 - Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein - Google Patents
Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikreinInfo
- Publication number
- MA45130B1 MA45130B1 MA45130A MA45130A MA45130B1 MA 45130 B1 MA45130 B1 MA 45130B1 MA 45130 A MA45130 A MA 45130A MA 45130 A MA45130 A MA 45130A MA 45130 B1 MA45130 B1 MA 45130B1
- Authority
- MA
- Morocco
- Prior art keywords
- methyl
- oxopyridin
- methoxypyridin
- methoxymethyl
- carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
L'invention concerne de nouveaux polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[(2-oxopyridin-1-yl))méthyl]phényl}méthyl)pyrazole-4-carboxamide et des sels de ceux-ci, des compositions pharmaceutiques contenant ces composés et leur utilisation comme inhibiteurs de la kallicréine à des fins thérapeutiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1609607.5A GB201609607D0 (en) | 2016-06-01 | 2016-06-01 | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
PCT/GB2017/051579 WO2017208005A1 (fr) | 2016-06-01 | 2017-06-01 | Polymorphes de n-[(3-fluoro-4-méthoxypyridin-2-yl)méthyl]-3-(méthoxyméthyl)-1-({4-[2-oxopyridin-1-yl)méthyl]phényl}méthyl)pyrazole-4-carboxamide utilisés comme inhibiteurs de la kallicréine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA45130A MA45130A (fr) | 2019-04-10 |
MA45130B1 true MA45130B1 (fr) | 2022-10-31 |
Family
ID=56410856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA45130A MA45130B1 (fr) | 2016-06-01 | 2017-06-01 | Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein |
Country Status (25)
Country | Link |
---|---|
US (2) | US11230537B2 (fr) |
EP (2) | EP4151630A1 (fr) |
JP (2) | JP6957516B2 (fr) |
KR (1) | KR102425918B1 (fr) |
CN (1) | CN109379891B (fr) |
AU (1) | AU2017273136B2 (fr) |
BR (1) | BR112018073521B1 (fr) |
CA (1) | CA3025720A1 (fr) |
DK (1) | DK3464265T3 (fr) |
ES (1) | ES2927779T3 (fr) |
GB (1) | GB201609607D0 (fr) |
HR (1) | HRP20221019T1 (fr) |
HU (1) | HUE059165T2 (fr) |
IL (1) | IL263222B (fr) |
LT (1) | LT3464265T (fr) |
MA (1) | MA45130B1 (fr) |
MD (1) | MD3464265T2 (fr) |
MX (1) | MX2018014700A (fr) |
PL (1) | PL3464265T3 (fr) |
PT (1) | PT3464265T (fr) |
RS (1) | RS63604B1 (fr) |
RU (1) | RU2756273C2 (fr) |
SI (1) | SI3464265T1 (fr) |
WO (1) | WO2017208005A1 (fr) |
ZA (1) | ZA201808638B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
KR102424709B1 (ko) | 2016-05-31 | 2022-07-22 | 칼비스타 파마슈티컬즈 리미티드 | 혈장 칼리크레인 저해제로서 피라졸 유도체 |
GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
JP2021517893A (ja) | 2018-03-13 | 2021-07-29 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用 |
EP4010333A1 (fr) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
WO2021055589A1 (fr) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Inhibiteurs hétéroaryles de la kallicréine plasmatique |
US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
CN111875557B (zh) * | 2020-08-19 | 2023-06-02 | 南通大学 | 一种噻唑类衍生物及其合成方法 |
EP4232031A1 (fr) * | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Traitements de l'oedème de quincke |
JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
BR0009721A (pt) | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
NZ530028A (en) | 1999-12-08 | 2005-08-26 | Pharmacia Corp | Process for producing eplerenone crystalline form exhibiting enhanced dissolution rate |
SI1441734T1 (sl) | 2001-10-26 | 2007-08-31 | Angeletti P Ist Richerche Bio | Dihidropirimidin karboksamidni inhibitorji HIV-integraze |
CA2465207C (fr) | 2001-11-01 | 2011-01-04 | Icagen, Inc. | Pyrazole-amides et -sulfonamides |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
CA2483159C (fr) | 2002-04-26 | 2010-08-10 | Eli Lilly And Company | Derives de triazole en tant qu'antagonistes des recepteurs de la tachykinine |
EP1426364A1 (fr) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Dérivés d'imidazole comme inhibiteurs du facteur Xa |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
EP2308848A1 (fr) | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Amides derives quinoliniques modulant le recepteur VR1 vanilloide |
EP2281885A1 (fr) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination thérapeutique pour le traitement des troubles oculaires néovasculaires |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (fr) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Dérivés de pyrrole en tant qu'inhibiteurs du facteur xa |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
DK1784402T3 (da) | 2004-09-03 | 2011-11-14 | Yuhan Corp | Pyrrolo[3,2-c]pyridinderivater samt fremgangsmåder til deres fremstilling |
EP2500031A3 (fr) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions et procédés de traitement de la perméabilité vasculaire |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
AU2006240551A1 (en) | 2005-04-28 | 2006-11-02 | Dsm Ip Assets B.V. | Pharmaceutical dosage forms comprising a lipid phase |
KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
MX2009000117A (es) | 2006-07-06 | 2009-01-23 | Glaxo Group Ltd | N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso. |
CA2658523C (fr) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibiteurs de kallicreine plasmatique |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
MX2009007050A (es) | 2006-12-29 | 2009-09-23 | Abbott Gmbh & Co Kg | Compuestos de carboxamida y su uso como inhibidores de calpaina. |
US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
EP2125816A2 (fr) | 2007-03-07 | 2009-12-02 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de métalloprotéase contenant une fraction hétérocyclique |
RU2464262C2 (ru) | 2007-03-30 | 2012-10-20 | Санофи-Авентис | Пиримидингидразидные соединения как ингибиторы pgds |
KR20090127435A (ko) | 2007-04-03 | 2009-12-11 | 글락소 그룹 리미티드 | P2x7 조절제로서의 이미다졸리딘 카르복스아미드 유도체 |
CL2008002172A1 (es) | 2007-07-26 | 2008-11-21 | Syngenta Participations Ag | Compuestos derivados de pirazol-etiloxiamidas; compuestos intermediarios; metodo para controlar o prevenir la infestacion de plantas utiles por parte de microorganismos fitopatogenos; y composicion para controlar y proteger contra microorganismos fitopatogenos. |
US20110105567A1 (en) | 2007-08-22 | 2011-05-05 | Allergan, Inc. | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity |
EP2219646A4 (fr) | 2007-12-21 | 2010-12-22 | Univ Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
WO2009083553A1 (fr) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Composés azines en tant qu'activateurs de glucokinase |
EP2259679A4 (fr) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | Méthodes de traitement de troubles associés à la kallikréine |
WO2009106980A2 (fr) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Dérivés d'indazole |
ES2380648T3 (es) | 2008-03-13 | 2012-05-17 | Bristol-Myers Squibb Company | Derivados de piridazina como inhibidores del factor XIA |
JP5461398B2 (ja) | 2008-07-08 | 2014-04-02 | 第一三共株式会社 | 含窒素芳香族ヘテロシクリル化合物 |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
US8609866B2 (en) | 2009-12-18 | 2013-12-17 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
US8598206B2 (en) | 2010-01-28 | 2013-12-03 | The Medicines Company (Leipzig) Gmbh | Trypsin-like serine protease inhibitors, and their preparation and use |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
US8921319B2 (en) | 2010-07-07 | 2014-12-30 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
WO2012009009A2 (fr) | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate |
US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
EP2458315B1 (fr) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Echangeur thermique régénératif doté d'un joint de rotor forcé |
EP2697196A1 (fr) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Promédicaments d'inhibiteurs de la kallicréine plasmatique |
RU2573611C2 (ru) * | 2011-06-08 | 2016-01-20 | Майкро Моушн, Инк. | Способ и устройство для определения и контроля статического давления флюида с помощью вибрационного измерителя |
WO2012174362A1 (fr) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Dérivés de pyrazole utilisés en tant qu'antagonistes du récepteur de type 1 des cannabinoïdes |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
EP2760829B1 (fr) | 2011-09-27 | 2016-05-18 | Bristol-Myers Squibb Company | Dérivés de pyrrolinone-carboxamide utiles comme inhibiteurs de lipase endothéliale |
EP2760828B1 (fr) | 2011-09-27 | 2015-10-21 | Bristol-Myers Squibb Company | Composés de pyrrolinone-carboxamide utiles en tant qu'inhibiteurs de lipase endothéliale |
EP2807156A1 (fr) | 2012-01-27 | 2014-12-03 | Novartis AG | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la kallicréine plasmatique |
WO2013111108A1 (fr) * | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique |
CA2862289C (fr) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification par methylation, leurs compositions et utilisations |
US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
CA2894642A1 (fr) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Derives pyrimidone et leur utilisation dans le traitement, l'amelioration ou la prevention d'une maladie virale |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
IL239682B (en) * | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
CA2897336C (fr) | 2013-01-20 | 2023-10-17 | Dyax Corp. | Evaluation et traitement des troubles dans lesquels intervient pkal |
CN108354933A (zh) | 2013-03-15 | 2018-08-03 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
HUE057851T2 (hu) | 2013-05-23 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorai |
WO2015022546A1 (fr) | 2013-08-14 | 2015-02-19 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
KR20160106627A (ko) | 2013-12-30 | 2016-09-12 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
SG11201607267SA (en) | 2014-03-07 | 2016-09-29 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
WO2015171526A2 (fr) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Composés de pyrazolopyridine tricycliques |
WO2015171527A1 (fr) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine, pyrazolopyrimidine et composés apparentés |
EP3169325B1 (fr) | 2014-07-16 | 2021-04-28 | Attune Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
EP3182962B1 (fr) | 2014-08-22 | 2023-06-07 | Biocryst Pharmaceuticals, Inc. | Compositions et utilisations de dérivés d'amidine |
CA2960790A1 (fr) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
LT3261639T (lt) | 2015-02-27 | 2022-11-25 | Verseon International Corporation | Pakaitiniai pirazolo junginiai kaip serino proteazės inhibitoriai |
WO2017001936A2 (fr) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
CA2991171A1 (fr) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Composes inhibiteurs therapeutiques |
US10399961B2 (en) | 2015-10-27 | 2019-09-03 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
WO2017072021A1 (fr) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Utilisation de dérivés hétéroarylcarboxamides comme inhibiteurs de la kallicréine plasmatique |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
KR102424709B1 (ko) | 2016-05-31 | 2022-07-22 | 칼비스타 파마슈티컬즈 리미티드 | 혈장 칼리크레인 저해제로서 피라졸 유도체 |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
EP3481391A4 (fr) | 2016-07-11 | 2020-03-11 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
GB201713660D0 (en) | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
WO2019106359A1 (fr) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201721515D0 (en) | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
EP4010333A1 (fr) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
EP4017850A1 (fr) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzyme |
BR112022001341A2 (pt) | 2019-08-21 | 2022-03-22 | Kalvista Pharmaceuticals Ltd | Inibidores de enzima |
BR112022001054A2 (pt) | 2019-08-21 | 2022-03-15 | Kalvista Pharmaceuticals Ltd | Inibidores enzimáticos |
WO2021032936A1 (fr) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzymes |
GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
-
2016
- 2016-06-01 GB GBGB1609607.5A patent/GB201609607D0/en not_active Ceased
-
2017
- 2017-06-01 HU HUE17728614A patent/HUE059165T2/hu unknown
- 2017-06-01 PL PL17728614.3T patent/PL3464265T3/pl unknown
- 2017-06-01 MA MA45130A patent/MA45130B1/fr unknown
- 2017-06-01 IL IL263222A patent/IL263222B/en unknown
- 2017-06-01 AU AU2017273136A patent/AU2017273136B2/en active Active
- 2017-06-01 RU RU2018139276A patent/RU2756273C2/ru active
- 2017-06-01 BR BR112018073521-3A patent/BR112018073521B1/pt active IP Right Grant
- 2017-06-01 MX MX2018014700A patent/MX2018014700A/es unknown
- 2017-06-01 JP JP2018559929A patent/JP6957516B2/ja active Active
- 2017-06-01 RS RS20220860A patent/RS63604B1/sr unknown
- 2017-06-01 WO PCT/GB2017/051579 patent/WO2017208005A1/fr active Search and Examination
- 2017-06-01 EP EP22183889.9A patent/EP4151630A1/fr active Pending
- 2017-06-01 HR HRP20221019TT patent/HRP20221019T1/hr unknown
- 2017-06-01 ES ES17728614T patent/ES2927779T3/es active Active
- 2017-06-01 EP EP17728614.3A patent/EP3464265B1/fr active Active
- 2017-06-01 SI SI201731201T patent/SI3464265T1/sl unknown
- 2017-06-01 CN CN201780034393.XA patent/CN109379891B/zh active Active
- 2017-06-01 MD MDE20190411T patent/MD3464265T2/ro unknown
- 2017-06-01 CA CA3025720A patent/CA3025720A1/fr active Pending
- 2017-06-01 US US16/303,334 patent/US11230537B2/en active Active
- 2017-06-01 LT LTEPPCT/GB2017/051579T patent/LT3464265T/lt unknown
- 2017-06-01 PT PT177286143T patent/PT3464265T/pt unknown
- 2017-06-01 DK DK17728614.3T patent/DK3464265T3/da active
- 2017-06-01 KR KR1020187038208A patent/KR102425918B1/ko active IP Right Grant
-
2018
- 2018-12-20 ZA ZA2018/08638A patent/ZA201808638B/en unknown
-
2021
- 2021-10-06 JP JP2021164519A patent/JP7383676B2/ja active Active
- 2021-10-20 US US17/505,906 patent/US11739068B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45130B1 (fr) | Polymorphes du n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole-4-carboxamide en tant qu'inhibiteurs de kallikrein | |
EA202091506A1 (ru) | Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
EA201992128A1 (ru) | Конденсированные имидазопиперидиновые ингибиторы jak | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
MA35716B1 (fr) | Formulations pharmaceutiques | |
EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
EA201890534A1 (ru) | Новые аннелированные феноксиацетамиды | |
TR201909997T4 (tr) | 5-HT4 reseptör agonistleri olarak amid bileşikleri. | |
EA201992413A1 (ru) | Противогрибковые средства, используемые в комбинации | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
BR112017012547A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas |